Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design — Hironori Hara (2022) | RDL Network
Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design
Background
Current ESC guidelines recommend the use of intra-coronary pressure guidewires for functional assessment of intermediate-grade coronary stenoses. Angiography-derived quantitative flow ratio (QFR) is a novel method of assessing these stenoses, and guiding percutaneous coronary intervention (PCI).
Methods/Design
The PIONEER IV trial is a prospective, all-comers, multi-center trial, which will randomize 2,540 patients in a 1:1 ratio to PCI guided by angiography-derived physiology or usual care, with unrestricted use in both arms of the Healing-Targeted Supreme sirolimus-eluting stent (HT Supreme). The stent's fast, biologically healthy, and robust endothelial coverage allows for short dual-antiplatelet therapy (DAPT); hence the antiplatelet regimen of choice is 1-month DAPT, followed by ticagrelor monotherapy. In the angiography-derived physiology guided arm, lesions will be functionally assessed using on-line QFR, with stenting indicated in lesions with a QFR ≤0.80. Post-stenting, QFR will be repeated in the stented vessel(s), with post-dilatation or additional stenting recommended if the QFR<0.91 distal to the stent, or if the delta QFR (across the stent) is >0.05. Usual care PCI is performed according to standard clinical practice. The primary endpoint is a non–inferiority comparison of the patient-oriented composite endpoint (POCE) of all-cause death, any stroke, any myocardial infarction, or any clinically, and physiologically driven revascularization with a non–inferiority risk-difference margin of 3.2%, at 1-year post-procedure. Clinical follow-up will be up to 3 years.
Summary
The PIONEER IV trial aims to demonstrate non–inferiority of QFR-guided PCI to usual care PCI with respect to POCE at 1-year in patients treated with HT Supreme stents and ticagrelor monotherapy.
Clinical Trial Registration
ClinicalTrials.gov
Unique Identifier
NCT04923191
Classifications
Interventional Cardiology
Patrick W. Serruys, Kuniaki Takahashi, Norihiro Kogame, Ply Chichareon, Rodrigo Modolo, Chun Chin Chang, Mariusz Tomaniak, Hidenori Komiyama, Christian W. Hamm, Philippe Gabríel Steg, H P Stoll, Yoshinobu Onuma, Marco Valgimigli, Stephan Windecker, Pascal Vranckx
Xuegai He, Bei Wang, Tzung‐Yi Tsai, P Chennigahoshalli Revaiah, Joanna J. Wykrzykowska, Faisal Sharif, Liesbeth Rosseel, Johan H. C. Reiber, Yoshinobu Onuma, Patrick W. Serruys
Lei Song, Shengxian Tu, Zhongwei Sun, Yang Wang, Daixin Ding, Changdong Guan, Lihua Xie, Javier Escaned, William F. Fearon, Ajay J. Kirtane, Patrick W. Serruys, William Wijns, Stephan Windecker, Martin B. Leon, Gregg W. Stone, Shubin Qiao, Bo Xu
Rodrigo Modolo, Ply Chichareon, Ana Paula de Faria, Philippe Gabríel Steg, Christian W. Hamm, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Yoshinobu Onuma, Patrick W. Serruys
Discussion(0)
No comments yet. Be the first to comment.